OUTLOOK THERAPEUTICS, INC.
OTLKLoading price...
Overview
Previous Close0.9602
Open0.9499
Ask1.2300
Bid0.7000
Day's Range0.9410 - 1.0400
52 Week Range0.1610 - 3.3900
PE Ratio(TTM)--
Market Cap194.48M
Volume1.92M
Avg. Volume22.39M
12 Months Earnings-159.13M
12 Months Revenue0.00
Profit/Loss
| PARTICULARS | TTM | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 59.86M | 53.13M | 63.07M | 51.73M | 36.31M |
| Profit after Tax (Net Income) | -159.13M | -58.98M | -66.05M | -53.16M | -35.24M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Iselin, United States
Website: https://outlooktherapeutics.com
President, CEO & Director: Mr. Robert Charles Jahr
Employees: 17
About Company:
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.